IL1B and Marchiafava-Bignami disease: Twelve weeks of IL-1 inhibition with rilonacept did not significantly change any of the measured markers of CKD-MBD (serum calcium, phosphorus, 25(OH)D, 1,25(OH)2D, 24,25(OH)2D3, intact parathyroid hormone (iPTH), and FGF23) as compared to the placebo group (Table 2).